Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange about the schedule of an earnings call for the unaudited financial results for the quarter ended June 30, 2026. The call is scheduled to be held on August 03, 2026, from 8:30 am to 9:30 am IST.

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 02, 2026, titled "Glenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancer". The company announced the advancement of its multi-country Phase 3 clinical trial for Trastuzumab rezetecan, a HER2-targeted antibody drug conjugate, for patients with platinum-resistant ovarian cancer.